An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
Bethesda, United States. In Leuk Res, 31 Oct 2014
Moxetumomab pasudotox (HA22) is a recombinant immunotoxin, now in clinical trials, that combines an anti-CD22-Fv with a 38-kDa fragment of Pseudomonas exotoxin A. To produce a less immunogenic molecule without reducing the half-life in circulation, we constructed LMB11 combining an anti-CD22 Fab with a less immunogenic version of PE38.
Temporal expression pattern of Fkbp8 in rodent cochlea.
Tübingen, Germany. In Cell Physiol Biochem, 2010
In pre-hearing time Fkbp8-specific signal was also observed in the tectorial membrane, whose alpha- and beta-Tectorin components show similar time-dependent expression of mRNA as Fkbp8.
FK506 binding proteins as targets in anticancer therapy.
Napoli, Italy. In Anticancer Agents Med Chem, 2010
Recent studies have focused on FKBPs in apoptosis regulation: Targeting of FKBP12 promotes apoptosis in chronic lymphocytic leukemia, FKBP38 knockdown sensitizes hepatoma cells to apoptosis, and FKBP51 silencing overcomes resistance to apoptosis in acute lymphoblastic leukemia, prostate cancer, melanoma, and glioma.